JP2023526836A5 - - Google Patents
Info
- Publication number
- JP2023526836A5 JP2023526836A5 JP2022570454A JP2022570454A JP2023526836A5 JP 2023526836 A5 JP2023526836 A5 JP 2023526836A5 JP 2022570454 A JP2022570454 A JP 2022570454A JP 2022570454 A JP2022570454 A JP 2022570454A JP 2023526836 A5 JP2023526836 A5 JP 2023526836A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- cov
- sars
- mek inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20175739.0 | 2020-05-20 | ||
| EP20175739.0A EP3912623B1 (en) | 2020-05-20 | 2020-05-20 | Pd-0184264 for the treatment of coronavirus infections and/or covid-19 cytokine storm |
| PCT/EP2021/063485 WO2021234097A1 (en) | 2020-05-20 | 2021-05-20 | Mek-inhibitors for the treatment or prevention of coronavirus infections and/or covid-19 cytokine storm |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023526836A JP2023526836A (ja) | 2023-06-23 |
| JP2023526836A5 true JP2023526836A5 (https=) | 2024-05-30 |
Family
ID=70802645
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022570454A Pending JP2023526836A (ja) | 2020-05-20 | 2021-05-20 | コロナウイルス感染症および／またはｃｏｖｉｄ－１９サイトカインストームの処置または予防のためのｍｅｋ阻害剤 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230241014A1 (https=) |
| EP (2) | EP3912623B1 (https=) |
| JP (1) | JP2023526836A (https=) |
| KR (1) | KR20230013077A (https=) |
| CN (1) | CN116635022A (https=) |
| AU (1) | AU2021277517A1 (https=) |
| BR (1) | BR112022023013A2 (https=) |
| CA (1) | CA3178137A1 (https=) |
| ES (1) | ES2995196T3 (https=) |
| MX (1) | MX2022014561A (https=) |
| WO (1) | WO2021234097A1 (https=) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3973960B1 (en) | 2017-10-17 | 2025-09-03 | Atriva Therapeutics GmbH | Novel mek-inhibitor for the treatment of viral and bacterial infections |
| LU101183B1 (en) * | 2019-04-16 | 2020-10-16 | Atriva Therapeutics Gmbh | Novel mek-inhibitor for the treatment of viral and bacterial infections |
| AU2021206684B2 (en) | 2020-01-10 | 2024-01-18 | Immuneering Corporation | MEK inhibitors and therapeutic uses thereof |
| WO2023084489A1 (en) * | 2021-11-15 | 2023-05-19 | Pfizer Inc. | Methods of treating coronavirus disease 2019 |
| EP4186500A1 (en) * | 2021-11-24 | 2023-05-31 | Atriva Therapeutics GmbH | Mek inhibitors for the prevention and treatment of long covid syndrome |
| WO2024042050A1 (en) * | 2022-08-22 | 2024-02-29 | Atriva Therapeutics Gmbh | Use of mek1/2 inhibitors to synergistically potentiate the antiviral effect of direct-acting anti-coronavirus drugs |
| US20240165099A1 (en) * | 2022-09-30 | 2024-05-23 | 60 Degrees Pharmaceuticals Llc | Methods for the treatment and prevention of diseases or infections with mcp-1 involvement by administration of tafenoquine |
| CN116270588B (zh) * | 2022-12-26 | 2025-07-25 | 中国科学技术大学 | Mek1/2抑制剂u0126在治疗car t细胞引起的crs中的应用 |
| TW202508595A (zh) | 2023-05-04 | 2025-03-01 | 美商銳新醫藥公司 | 用於ｒａｓ相關疾病或病症之組合療法 |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| TW202547461A (zh) | 2024-05-17 | 2025-12-16 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1420778B1 (en) * | 2001-03-06 | 2006-11-22 | Dorian Bevec | Use of mek inhibitors for treating virus induced hemorrhagic shock or fever |
| EP3973960B1 (en) * | 2017-10-17 | 2025-09-03 | Atriva Therapeutics GmbH | Novel mek-inhibitor for the treatment of viral and bacterial infections |
| LU101183B1 (en) * | 2019-04-16 | 2020-10-16 | Atriva Therapeutics Gmbh | Novel mek-inhibitor for the treatment of viral and bacterial infections |
-
2020
- 2020-05-20 EP EP20175739.0A patent/EP3912623B1/en active Active
- 2020-05-20 ES ES20175739T patent/ES2995196T3/es active Active
-
2021
- 2021-05-20 CN CN202180059642.7A patent/CN116635022A/zh active Pending
- 2021-05-20 JP JP2022570454A patent/JP2023526836A/ja active Pending
- 2021-05-20 CA CA3178137A patent/CA3178137A1/en active Pending
- 2021-05-20 KR KR1020227044294A patent/KR20230013077A/ko active Pending
- 2021-05-20 AU AU2021277517A patent/AU2021277517A1/en active Pending
- 2021-05-20 EP EP21731684.3A patent/EP4153159A1/en active Pending
- 2021-05-20 US US17/999,185 patent/US20230241014A1/en active Pending
- 2021-05-20 MX MX2022014561A patent/MX2022014561A/es unknown
- 2021-05-20 WO PCT/EP2021/063485 patent/WO2021234097A1/en not_active Ceased
- 2021-05-20 BR BR112022023013A patent/BR112022023013A2/pt unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023526836A5 (https=) | ||
| CN114786659B (zh) | 用于治疗汉坦病毒感染的mek抑制剂 | |
| Yousefi et al. | A global treatments for coronaviruses including COVID‐19 | |
| Barnard et al. | Evaluation of immunomodulators, interferons and known in vitro SARS-coV inhibitors for inhibition of SARS-coV replication in BALB/c mice | |
| JP5470047B2 (ja) | 抗ウイルス組成物及び使用方法 | |
| CN113244212B (zh) | 黄芩素在制备预防和/或治疗新型冠状病毒感染疾病的药物中的应用 | |
| KR102910416B1 (ko) | 유행성 rna 바이러스 감염질환의 예방 또는 치료용 약제학적 조성물 | |
| KR20210035339A (ko) | 바이러스 감염을 치료하기 위한 티아졸리드 화합물 | |
| EP4613275A1 (en) | Pharmaceutical use of nucleoside compound | |
| WO2023165566A1 (zh) | 治疗、预防由病毒感染引起的相关疾病的药物及其用途 | |
| EP3934653B1 (en) | Azelastine as antiviral treatment | |
| CN115397410A (zh) | 用于治疗、预防或限制病毒感染发生的方法和组合物 | |
| US4828830A (en) | Method and composition for prophylaxis and treatment of viral infections | |
| WO2017201030A1 (en) | Methods of treating viral infection | |
| RU2555765C2 (ru) | Пироксикам для профилактического и терапевтического лечения герпетических инфекций | |
| Steffenhagen et al. | Evaluation of 6-azauridine and S-iododeoxyuridine in the treatment of experimental viral infections | |
| Cao et al. | Xiao-Er-Kang-Du capsules regulate autophagy against the influenza B virus (Victoria strain) through the mTOR/ULK1/Beclin1/VPS34 pathway | |
| WO2022079496A1 (en) | A pharmaceutical composition of nitazoxanide, albendazole and pyrantel and method thereof | |
| EP4431103A1 (en) | Formulations comprising heparan sulfate for the treatment and prevention of viral infections caused by orthocoronaviridae | |
| US20230030607A1 (en) | Novel oxygen pulse therapy method for treating COVID19 and viral, bacterial, fungal or parasitic respiratory and other diseases | |
| WO2021205153A1 (en) | New use of n,n-bis-2-mercaptoethyl isophthalamide | |
| WO2022123323A1 (en) | A pharmaceutical composition of artesunate and mefloquine and method thereof | |
| US20250073190A1 (en) | Compositions and Use of N-Chlorotaurine for Treatment and Prevention of Respiratory Infections | |
| CN114732815B (zh) | 一种化合物在制备抗病毒药物中的用途及应用 | |
| US20240115622A1 (en) | Formulation for the prevention and/or treatment of covid-19 |